Patents by Inventor Rolf Joseph Craven

Rolf Joseph Craven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Secreted tumor-associated cytochrome as a blood-based biomarker for cancer
    Patent number: 10288626
    Abstract: Disclosed herein are methods for detecting Pgrmc1 in bodily fluids, e.g., blood, plasma and serum, wherein detection of Pgrmc1 is a biomarker for the presence of cancer, e.g., lung cancer or head or neck cancer. Pgrmc1 levels in bodily fluids may be used to predict patient prognosis, e.g., survival and response to therapy.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: May 14, 2019
    Assignee: University of Kentucky Research Foundation
    Inventor: Rolf Joseph Craven
  • AG-205 for the treatment of breast cancer
    Patent number: 9724337
    Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: August 8, 2017
    Assignee: University of Kentucky Research Foundation
    Inventor: Rolf Joseph Craven
  • Secreted Tumor-Associated Cytochrome as a Blood-Based Biomarker for Cancer
    Publication number: 20140106375
    Abstract: Disclosed herein are methods for detecting Pgrmc1 in bodily fluids, e.g., blood, plasma and serum, wherein detection of Pgrmc1 is a biomarker for the presence of cancer, e.g., lung cancer or head or neck cancer. Pgrmc1 levels in bodily fluids may be used to predict patient prognosis, e.g., survival and response to therapy.
    Type: Application
    Filed: September 16, 2013
    Publication date: April 17, 2014
    Applicant: University of Kentucky Research Foundation
    Inventor: Rolf Joseph CRAVEN
  • DRUG CLASS FOR THE TREATMENT OF CANCER
    Publication number: 20100266540
    Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.
    Type: Application
    Filed: April 20, 2010
    Publication date: October 21, 2010
    Applicant: University of Kentucky Research Foundation
    Inventor: Rolf Joseph CRAVEN
  • Hpr6 mutants and uses thereof
    Patent number: 7342100
    Abstract: Methods and agents that interfere with Hpr6 function in non-sarcoma tumor cells are disclosed. Anti-Hpr6 agents are used to enhance the killing effect of anti-cancer agents in non-sarcoma tumor cells and to teat non-sarcoma tumors.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: March 11, 2008
    Assignee: University of Kentucky Research Foundation
    Inventor: Rolf Joseph Craven
  • Hpr6 mutants and uses thereof
    Publication number: 20050272045
    Abstract: Methods and agents that interfere with Hpr6 function in non-sarcoma tumor cells are disclosed. Anti-Hpr6 agents are used to enhance the killing effect of anti-cancer agents in non-sarcoma tumor cells and to teat non-sarcoma tumors.
    Type: Application
    Filed: June 4, 2004
    Publication date: December 8, 2005
    Inventor: Rolf Joseph Craven